Research area
Cell & Gene Therapy
Therapeutic cells, gene-based treatments and biological regeneration, including engineered immune cells for cancer.
-
Evidence date ·What early replacement of the missing creatine transporter changed in mouse brain function
Peer-Reviewed PaperTracked over timeNewborn gene delivery changed brain scans and object recognition in mice with creatine transporter deficiency, but healthy controls did worse on a working-memory test.
-
Evidence date ·Can patient skin cells make their own creatine when import fails?
Peer-Reviewed PaperTracked over timeResearchers delivered two creatine-making genes to cultured patient skin cells, raising intracellular creatine while leaving brain treatment untested.
-
Evidence date ·Brain-directed gene delivery protected movement and muscle development in rats with creatine transport deficiency
Peer-Reviewed PaperTracked over timeEarly gene delivery protected movement and muscle development in rats with creatine transporter deficiency. Human benefit remains untested.
-
Evidence date ·What engineered immune cells must overcome inside a breast tumor
Review or Meta-AnalysisA 2023 review explains variable tumor targets, healthy-tissue recognition and local immune suppression, separating preclinical ideas from patient benefit.
-
Evidence date ·Recognition is only the start for CAR T cells in solid tumors
Review or Meta-AnalysisA 2023 review examines ways to help CAR T cells reach solid tumors and stay active inside them, but does not establish the best delivery route for patients.
-
Evidence date ·How engineered cancer-fighting cells face solid tumors
Review or Meta-AnalysisA June 2023 review explains a 63% response rate in childhood neuroblastoma and why engineered immune cells still struggle in common solid tumors.
-
Evidence date ·How non-viral engineering turns natural killer cells into cancer-targeting cells
Review or Meta-AnalysisTracked over timeAn April 2025 review explains how temporary receptors, lasting gene changes, cell production and freezing shape ready-to-use cancer therapies.
-
Evidence date ·How receptor design changes what engineered natural killer cells can do against leukemia
Peer-Reviewed PaperTracked over timeSeven receptors changed how cord-blood natural killer cells killed leukemia cells and persisted in mice. Patient benefit remains untested.
-
Evidence date ·Engineered natural killer cells deliver an extra protein to mouse breast tumors
Peer-Reviewed PaperTracked over timeA 2023 mouse study tested HER2-targeting natural killer cells that release soluble PD-1, including a trastuzumab-resistant breast-cancer model.
-
Evidence date ·What natural killer cells need to do after patients receive them
Review or Meta-AnalysisA 2023 review traces natural killer cells from expansion to persistence, tumor access, and cancer-cell killing; its abstract summarizes early trials.